Topiramate

Generic Name: Topiramate

Brand Names: Eprontia, Qsymia, Qudexy, Topamax, Trokendi

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁NO_₈S

CAS Number: 97240-79-4

Unique Ingredient Identifier: 0H73WJJ391

Background: Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...

Indication: Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...

Associated Conditions: Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight

Associated Therapies: Chronic Weight Management therapy, Weight Reduction

Clinical Trials

Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia

Phase 3

Conditions: Alcohol Dependence

Interventions: Drug: Naltrexone
Drug: Topiramate

First Posted Date: 2018-03-27

Last Posted Date: 2018-05-11

Lead Sponsor: South West Sydney Local Health District

Target Recruit Count: 180

Registration Number: NCT03479086

Locations: 🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

Phase 1

Completed

Conditions: Contraception
Migraine;Menstrual
Migraine

Interventions: Drug: Topiramate

First Posted Date: 2017-11-07

Last Posted Date: 2022-07-13

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 48

Registration Number: NCT03335163

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Lasmiditan
Drug: Topiramate

First Posted Date: 2017-10-12

Last Posted Date: 2019-11-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT03308669

Locations: 🇺🇸
Covance Madison CRU, Madison, Wisconsin, United States

Population Pharmacokinetics of Antiepileptic in Pediatrics

First Posted Date: 2017-06-22

Last Posted Date: 2024-10-30

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 1000

Registration Number: NCT03196466

Locations: 🇫🇷
AP-HP Cochin, Paris, France

Topiramate and Prolonged Exposure

Phase 2

Completed

Conditions: PTSD and Alcohol Use Disorder

Interventions: Drug: topiramate
Behavioral: prolonged exposure
Drug: placebo

First Posted Date: 2017-06-06

Last Posted Date: 2023-11-18

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 100

Registration Number: NCT03176953

Locations: 🇺🇸
VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States

Topiramate Treatment of Alcohol Use Disorders in African Americans

Phase 4

Terminated

Conditions: Alcohol Use Disorder

Interventions: Drug: placebo
Drug: Topiramate

First Posted Date: 2017-01-12

Last Posted Date: 2023-03-23

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 79

Registration Number: NCT03018704

Locations: 🇺🇸
Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States
🇺🇸
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States

Physiologic Effects of Topiramate on Cognition

Phase 1

Completed

Conditions: Alteration of Cognitive Function

Interventions: Drug: Placebo
Drug: Topiramate

First Posted Date: 2016-08-30

Last Posted Date: 2017-01-11

Lead Sponsor: University of Florida

Target Recruit Count: 11

Registration Number: NCT02884050

Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)

Phase 2

Completed

Conditions: Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome

Interventions: Other: Placebo
Drug: topiramate

First Posted Date: 2016-08-25

Last Posted Date: 2023-11-14

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 132

Registration Number: NCT02878798

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 17 locations

Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks

Phase 3

Terminated

Conditions: Prader-Willi Syndrome

Interventions: Drug: Placebo Comparator
Drug: Topiramate

First Posted Date: 2016-06-23

Last Posted Date: 2018-04-11

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 69

Registration Number: NCT02810483

Locations: 🇫🇷
Hôpital La Pitié Salpêtrière, Paris, France

Topiramate and Schizophrenia: Effects on Weight and Psychopathology

Not Applicable

Recruiting

Conditions: Schizophrenia, Schizoaffective Disorder

Interventions: Other: Placebo
Drug: Topiramate

First Posted Date: 2016-06-21

Last Posted Date: 2023-07-24

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 50

Registration Number: NCT02808533

Locations: 🇨🇦
Center for Addiction and Mental Health, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy